Megan Cheah

Megan Cheah

JOURNALIST

Megan was a journalist with The Business Times from June 2023 to June 2025. She covered companies and markets, with a focus on healthcare, medtech and pharmaceuticals. She also previously wrote about listed consumer companies. She graduated from Nanyang Technological University with a degree in communication studies. 

Funds from the Series D round will support the company’s registration trial, which started in February this year and involves 200 participants in multiple US sites.

Lightstone Ventures, Temasek’s ClavystBio co-lead Allay Therapeutics’ US$57.5 million Series D funding

The company’s technology is used to create analgesic products that can aid patients with post-surgical pain management and recuperation

Following the appeal, the judgement has been set aside and Dr Goh Jin Hian no longer has to pay damages to IPP.

Court partially allows Goh Jin Hian’s appeal, finds he did not breach duty by not probing IPP’s red flags

Dr Goh no longer has to pay damages to the insolvent marine-fuel supplier; he was previously liable for US$146 million plus interest

Singapore Paincare CEO Dr Bernard Lee (above) and COO Dr Jeffrey Loo are looking to take the company private at S$0.16 per share.
HOCK LOCK SIEW

The privatisation offer for this small Catalist company could cause SGX some discomfort

The proposal to take Singapore Paincare private comes a mere five years after IPO, and highlights the local bourse’s chronic lack of...

The benchmark Straits Times Index declined 0.6 per cent or 22.23 points to 3,894.6.

Singapore stocks fall as Trump tariffs resume for now; STI retreats 0.6%

Across the broader market, decliners beat gainers 248 to 209, with 1.3 billion securities worth S$3.3 billion changing hands

Despite the impact of medical inflation and the Ramadan fasting period on Malaysia, contributions from Island Hospital in Penang resulted in the segment’s revenue gaining 17 per cent year on year to RM1.1 billion.

Measures to address medical inflation could soften revenue, but issues have abated significantly: IHH Healthcare

CEO says group is now negotiating directly with insurers, offering more packages and discounts

The Enigma Health and Roche MOU signing. Seated in the front row from left: Dr Dario Heymann, CEO, Enigma Health and Yeoh Ying Ying, general manager of pharmaceuticals division at Roche. Back row from left: Associate Professor Daniel Ting, AI office director at SingHealth; Rahayu Mahzam, Minister of State for Health; and Frank Grutter, Ambassador of Switzerland to Singapore.

SingHealth Duke-NUS’ AI spinoff inks MOUs with Roche, ST Engineering to improve healthcare operations

Possible uses for the Enigma platform include accelerating clinical trial recruitment, checking specialised data

Perennial will lease around 105,000 square metres in the southeast tower of Yuesheng Plaza, adjacent to the Baiyun High Speed Railway station.

Perennial to invest one billion yuan to open two hospitals in Guangzhou

This includes a wholly foreign-owned general hospital, the group’s second in China

Increasing the safety profile of the stem cells is also important to TargaZyme’s multiplier technology, which is infused into patients as a drug.

‘A GPS for stem cells’: TargaZyme’s Singapore CEO wants to cure cancer

The company aims to develop cancer immunotherapies using its cell efficacy multiplier technology.

Ng Yao Loong, SGX head of equities, says: "We see discerning investors gravitate towards well-managed Reits with strong fundamentals."

Reit privatisation unsurprising amid higher-for-longer interest rates, but investment opportunities remain: SGX equities head

Real estate investment trusts have a lower correlation with macro uncertainties compared to equities and other asset classes, making the sector a...